These studies demonstrated that aCML is predominantly a JAK2 V617F negative neoplasm [120, 121] with mutation in the gene found in 4% to 8% of patients [11, 14, 70]. This evidence concerns the gene JAK2 and atypical chronic myeloid leukemia, BCR-ABL1 negative.